Bertrand Coiffier
Overview
Explore the profile of Bertrand Coiffier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
249
Citations
12363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Relecom A, Federico M, Connors J, Coiffier B, Biasoli I, Moccia A, et al.
Int J Environ Res Public Health
. 2020 Mar;
17(5).
PMID: 32182952
Hodgkin lymphoma is a haematological malignancy predominantly affecting young adults. Hodgkin lymphoma is a highly curable disease by current treatment standards. Latest treatment guidelines for Hodgkin lymphoma however imply access...
2.
Thieblemont C, Howlett S, Casasnovas R, Mounier N, Perrot A, Morschhauser F, et al.
Br J Haematol
. 2019 Nov;
189(1):84-96.
PMID: 31702836
Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study. This subpopulation...
3.
Sharman J, Coutre S, Furman R, Cheson B, Pagel J, Hillmen P, et al.
J Clin Oncol
. 2019 Apr;
37(16):1391-1402.
PMID: 30995176
Purpose: A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior...
4.
Ogura M, Sancho J, Cho S, Nakazawa H, Suzumiya J, Tumyan G, et al.
Lancet Haematol
. 2018 Nov;
5(11):e543-e553.
PMID: 30389036
Background: Studies in patients with rheumatoid arthritis and advanced follicular lymphoma have shown that CT-P10, a rituximab biosimilar, has equivalent or non-inferior efficacy and pharmacokinetics to rituximab. We aimed to...
5.
Federico M, Caballero Barrigon M, Marcheselli L, Tarantino V, Manni M, Sarkozy C, et al.
Lancet Haematol
. 2018 Aug;
5(8):e359-e367.
PMID: 30078408
Background: Histological transformation of follicular lymphoma to aggressive lymphoma is a serious event with a substantial effect on patient outcome. The aim of the Aristotle study was to assess the...
6.
Shi Q, Schmitz N, Ou F, Dixon J, Cunningham D, Pfreundschuh M, et al.
J Clin Oncol
. 2018 Jul;
36(25):2593-2602.
PMID: 29975624
Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point...
7.
Filliatre-Clement L, Maucort-Boulch D, Bourbon E, Karlin L, Safar V, Bachy E, et al.
Hematol Oncol
. 2018 May;
PMID: 29722049
In the rituximab era, one-third of diffuse large B-cell lymphoma patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy. Optimal management remains an unmet medical need. The aim of this study...
8.
Pettengell R, Coiffier B, Egorov A, Singer J, Sivcheva L
Clin Drug Investig
. 2018 Mar;
38(6):527-533.
PMID: 29564722
Background: Pixantrone is recommended in relapsed and refractory non-Hodgkin lymphoma (NHL) or heavily pretreated NHL patients. Its conditional approval in Europe was based on results from the open-label, randomized, phase...
9.
Tilly H, Salles G, Molina T, Casasnovas R, Morschhauser F, Coiffier B
J Clin Oncol
. 2018 Jan;
36(9):923.
PMID: 29369698
No abstract available.
10.
Rossi C, Mounier M, Brice P, Safar V, Nicolas-Virelizier E, Rey P, et al.
Oncotarget
. 2017 Nov;
8(49):85110-85119.
PMID: 29156707
Introduction: Infradiaphragmatic Hodgkin Lymphoma (IDHL) accounts for 3-11% of adult cases of stage I-II Hodgkin Lymphoma and the treatment strategy in IDHL is still heterogeneous. All previous published studies were...